Literature DB >> 8576932

Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension.

H Haikala1, J Levijoki, I B Lindén.   

Abstract

The effects of various calcium sensitizers on myosin-actin crossbridge kinetics were evaluated in intact, paced guinea-pig papillary muscle by analysing the velocity of the development of isometric tension (dT/dt) in detail. The effect on association (the whole sequence of events from troponin onward) and dissociation rates of crossbridges was estimated from the rising phase and from the early decay phase of the normalized dT/dt curve. Levosimendan, a calcium sensitizer acting through troponin C, accelerated the proportional association rate and decelerated the dissociation rate of crossbridges. The effect of levosimendan on crossbridge kinetics occurred before the peak twitch tension was achieved. Thus, the compound did not change the actual relaxation phase of twitch tension. Since the effect on the association was more pronounced than on the dissociation of crossbridges, levosimendan shifted the entire twitch tension curve to the left. Based on the dissociation rate analysis levosimendan seems to act preferentially as a calcium sensitizer at low concentrations. At high concentrations the phosphodiesterase III (PDE III) inhibitory properties of levosimendan modulated its effect on the early relaxation processes. In contrast, PDE III inhibition is probably the primary mechanism of action for MCI-154. Pimobendan, and EMD 53998 at low concentrations, whereas their direct effects on crossbridge kinetics contributed to the positive inotropic action at high concentrations. The calcium sensitizing mechanisms of these compounds seemed to be based almost exclusively on the decelerating effect on dissociation of crossbridges.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8576932     DOI: 10.1016/s0022-2828(95)91371-8

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  10 in total

1.  Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model.

Authors:  E du Toit; D Hofmann; J McCarthy; C Pineda
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

2.  Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium.

Authors:  Reiko Takahashi; Masao Endoh
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

3.  The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts.

Authors:  Matthias Behrends; Jürgen Peters
Journal:  Intensive Care Med       Date:  2003-07-17       Impact factor: 17.440

Review 4.  [Levosimendan. Clinical indications of a new vasoactive substance].

Authors:  J-P Braun; U Döpfmer; M Kastrup; I Roots; A Borges; M Schneider; P Dohmen; W Kox; C Spies
Journal:  Anaesthesist       Date:  2004-02       Impact factor: 1.041

5.  Population pharmacokinetics of levosimendan in patients with congestive heart failure.

Authors:  E Niclas Jonsson; Saila Antila; Lynn McFadyen; Lasse Lehtonen; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

6.  Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Ammar Al-Chalabi; Pamela Shaw; P Nigel Leigh; Leonard van den Berg; Orla Hardiman; Albert Ludolph; Valtteri V Aho; Toni Sarapohja; Mikko Kuoppamäki
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-07-17       Impact factor: 10.154

7.  Functional human cell-based vascularised cardiac tissue model for biomedical research and testing.

Authors:  Maria Koivisto; Tuomas A Tolvanen; Tarja Toimela; Ilkka Miinalainen; Antti Kiviaho; Juha Kesseli; Matti Nykter; Lauri Eklund; Tuula Heinonen
Journal:  Sci Rep       Date:  2022-08-05       Impact factor: 4.996

Review 8.  [Levosimendan in cardiology and intensive care medicine].

Authors:  Georg Delle Karth; Gottfried Heinz
Journal:  Wien Klin Wochenschr       Date:  2004-01-31       Impact factor: 2.275

9.  Ischemia reperfusion dysfunction changes model-estimated kinetics of myofilament interaction due to inotropic drugs in isolated hearts.

Authors:  Samhita S Rhodes; Amadou K S Camara; Kristina M Ropella; Said H Audi; Matthias L Riess; Paul S Pagel; David F Stowe
Journal:  Biomed Eng Online       Date:  2006-03-02       Impact factor: 2.819

Review 10.  Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper.

Authors:  Bernard Cholley; Bruno Levy; Jean-Luc Fellahi; Dan Longrois; Julien Amour; Alexandre Ouattara; Alexandre Mebazaa
Journal:  Crit Care       Date:  2019-11-29       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.